Crinetics Pharmaceuticals Stock Investor Sentiment

CRNX Stock  USD 56.06  0.97  1.70%   
Slightly above 69% of Crinetics Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Crinetics Pharmaceuticals suggests that many traders are alarmed. Crinetics Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Crinetics Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.

Panic Vs Confidence

31

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Crinetics Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Crinetics Pharmaceuticals.

Crinetics Historical Sentiment

Although Crinetics Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Crinetics, such as negative comments on social media and news outlets, may cause fear in the market and push Crinetics Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Crinetics.
  

Crinetics Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Crinetics Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Crinetics Pharmaceuticals Historical Investor Sentiment

Investor biases related to Crinetics Pharmaceuticals' public news can be used to forecast risks associated with an investment in Crinetics. The trend in average sentiment can be used to explain how an investor holding Crinetics can time the market purely based on public headlines and social activities around Crinetics Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Crinetics Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Crinetics Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Crinetics Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Crinetics Pharmaceuticals.
few days ago at thelincolnianonline.com         
Crinetics Pharmaceuticals, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts
news
few days ago at thelincolnianonline.com         
Acquisition by Marc Wilson of 25000 shares of Crinetics Pharmaceuticals at 20.02 subject to Rule 16b...
news
few days ago at news.google.com         
Victory Capital Management Inc. Purchases 116,657 Shares of Crinetics Pharmaceuticals, Inc. - Market...
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Crinetics Pharmaceuticals Price Target Raised to 81.00
news
over a week ago at gurufocus.com         
EcoR1 Capital, LLC Reduces Stake in ITeos Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Steven Cohens Recent Transaction in Crinetics Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over a week ago at simplywall.st         
Crinetics Pharmaceuticals Third Quarter 2024 Earnings US0.96 loss per share
Simply Wall St News at Macroaxis
over a week ago at thelincolnianonline.com         
Crinetics Pharmaceuticals Announces Earnings Results, Misses Estimates By 0.05 EPS
news
over a week ago at gurufocus.com         
Driehaus Capital Management LLC Acquires Shares in Apogee Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Crinetics Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances and ...
Gurufocus Stories at Macroaxis
over a week ago at insidermonkey.com         
Crinetics Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a week ago at investing.com         
Crinetics unveils new NDC asset shares target raised to 81 by H.C. Wainwright
Investing News at Macroaxis
over a week ago at globenewswire.com         
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at ...
Macroaxis News: globenewswire.com
over a week ago at seekingalpha.com         
Crinetics Pharmaceuticals GAAP EPS of -0.96 misses by 0.05
seekingalpha News
over a week ago at globenewswire.com         
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants UnderNasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Crinetics Pharmaceuticals that are available to investors today. That information is available publicly through Crinetics media outlets and privately through word of mouth or via Crinetics internal channels. However, regardless of the origin, that massive amount of Crinetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Crinetics Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Crinetics Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Crinetics Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Crinetics Pharmaceuticals alpha.

Crinetics Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Long Term Investment Analysis - Stock Traders Daily
09/23/2024
2
Disposition of 14375 shares by Pizzuti Dana of Crinetics Pharmaceuticals at 54.63 subject to Rule 16b-3
10/03/2024
3
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635
10/10/2024
4
Crinetics Pharmaceuticals, Inc. Sees Large Growth in Short Interest
10/15/2024
5
Sage Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates
10/29/2024
6
Vanguard Group Incs Strategic Acquisition in Crinetics Pharmaceuticals Inc
11/05/2024
7
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society Annual Meeti...
11/12/2024
8
Crinetics Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances and ...
11/13/2024
9
Crinetics Pharmaceuticals Third Quarter 2024 Earnings US0.96 loss per share
11/14/2024
10
Crinetics Pharmaceuticals, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts
11/21/2024

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.